Cargando…
Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond
Multiomic analyses have shed light upon the molecular heterogeneity and complexity of triple-negative breast cancers (TNBCs). With increasing recognition that TNBC is not a single disease entity but encompasses different disease subtypes, a one-size-fits-all treatment paradigm has become obsolete. I...
Autores principales: | Chan, Jack J., Tan, Tira J. Y., Dent, Rebecca A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785914/ https://www.ncbi.nlm.nih.gov/pubmed/31636720 http://dx.doi.org/10.1177/1758835919880429 |
Ejemplares similares
-
Controversial issues in the neoadjuvant treatment of triple-negative breast cancer
por: Fitzpatrick, Amanda, et al.
Publicado: (2019) -
Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer
por: Simmons, Christine E., et al.
Publicado: (2020) -
Combined targeting EGFR and SRC as a potential novel therapeutic
approach for the treatment of triple negative breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2020) -
Pin1 plays a key role in the response to treatment and clinical outcome in triple negative breast cancer
por: Knowlson, Catherine, et al.
Publicado: (2020) -
Cytotoxic T-lymphocyte infiltration and chemokine predict long-term patient survival independently of tumor mutational burden in triple-negative breast cancer
por: Katsuta, Eriko, et al.
Publicado: (2021)